Clinical Trial Update: Low-dose IL-2 in Established T1D - The "PROREG" Study [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating low-dose interleukin-2 in established type 1 diabetes has been withdrawn from ClinicalTrials.gov.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Proleukin (aldesleukin)

Snippet

Sponsor: Jay S. Skyler | Conditions: Diabetes Mellitus, Type 1, Diabetes | Phase 1, Phase 2 | Status: WITHDRAWN